Abstracts tagged "Rheumatoid Factor"

Abstract Number: 0055 • ACR Convergence 2024
Activating STAT3 Mutations in CD8+ T Cells Correlate to Serological Positivity in Rheumatoid Arthritis
Katharine moosic¹, Thomas Olson², Mark Freijat³, samara khalique⁴, Cait Hamele¹, Bryna Shemo¹, Jesse Boodoo⁵, William Baker⁶, Gitanjali Khurana⁷, Matthew Schmachtenberg⁸, Tristin Duffy⁸, Aakrosh Ratan¹, Erika Darrah⁹, Felipe Andrade¹⁰, Marieke Jones⁸, Kristine Olson², David Feith¹, Thomas Loughran¹ and Donald Kimpel¹, ¹University of Virginia, Charlottesville, VA, ²Virginia Commonwealth University, Richmond, VA, ³Flow Rheumatology, Scottsdale, AZ, ⁴Carilion Clinic/ VirginiaTech, Salem, VA, ⁵Sarasota Arthritis Center, Sarasota, FL, ⁶Atrium Health, Charlotte, NC, ⁷University of Virginia, CROZET, VA, ⁸University of Virginia, Charlottesville, ⁹Johns Hopkins University, Baltimore, MD, ¹⁰The Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Large granular lymphocyte (LGL) leukemia is a rare hematologic malignancy characterized by clonal expansion of cytotoxic T-cells and frequent somatic activating STAT3 mutations. A…
Abstract Number: 2250 • ACR Convergence 2024
Cause Specific Mortality Differs in Rheumatoid Arthritis by Sex and Seropositivity
Elena Joerns¹, Ryan Lennon², Cynthia Crowson², Andrea Lopez-ruiz², Roslin Jose George², Vanessa Kronzer², John Davis² and Elena Myasoedova², ¹Mayo Clinic, Rochester, ²Mayo Clinic, Rochester, MN
Background/Purpose: Persons with rheumatoid arthritis (RA) have an increased risk of mortality compared to the general population. Seropositivity has been shown to be associated with…
Abstract Number: 0059 • ACR Convergence 2024
Fragment Crystallizable (Fc)-Free Certolizumab Pegol Is Not Bound by Rheumatoid Factors, While Fc Containing Biological DMARDsAre, Driving ImmuneComplex Formation and Cellular Clearance
Susanna R. Bidgood¹, Sophie Hopkin¹, Kathryn R. Malpas¹, David M. Kallenberg¹, Jacqueline O’Neill¹, Geofrey Odede¹, Bernard Lauwerys², Baran Ufuktepe³ and David Humphreys¹, ¹UCB Biopharma UK, Slough, United Kingdom, ²UCB Pharma, Brussels, Belgium, ³UCB Pharma, Istanbul, Turkey
Background/Purpose: RFs are polyclonal autoantibodies which bind the Fc domain of IgGs. Patients with RA and high RF levels have poorer prognosis, more severe progressive…
Abstract Number: 2266 • ACR Convergence 2024
Immunosuppressive Medications and Common Infections in Patients with Rheumatoid Arthritis
Michael George¹, Kelly Gavigan², Shilpa Venkatachalam³, David Curtis², Laura Stradford⁴, William Benjamin Nowell⁵, Fenglong Xie⁶, Joshua Baker¹ and Jeffrey Curtis⁷, ¹University of Pennsylvania, Philadelphia, PA, ²Global Healthy Living Foundation, Upper Nyack, NY, ³Global Healthy Living Foundation, New York, NY, ⁴Global Healthy Living Foundation, Nyack, NY, ⁵Regeneron, New York, NY, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Patients with RA are at increased risk of serious infection, but less is known about common, non-serious infections. Our prospective study aimed to assess…
Abstract Number: 0158 • ACR Convergence 2024
Rheumatoid Arthritis Testing Patterns by Physicians and Advanced Practice Providers from a National Commercial Laboratory, 2014 – 2023
Karis Lee¹, Min Kyung Lee², David Alfego³, Kristen Clark⁴ and Stanley Naides⁵, ¹Labcorp, Orlando, FL, ²Labcorp, San Diego, CA, ³Labcorp, Carlsbad, CA, ⁴Labcorp, Raleigh, NC, ⁵Labcorp, Dana Point, CA
Background/Purpose: With the commercialization of new diagnostic and monitoring tests for rheumatoid arthritis (RA) and an increasing number of advanced practice providers (APPs) in the…
Abstract Number: 2286 • ACR Convergence 2024
Certolizumab Inhibits Radiographic Progression Even in RA Patients with High Rheumatoid Factor Levels: A Pooled, Post-Hoc Analysis of Two Phase 3 Trials
Josef Smolen¹, Gerd Burmester², Yoshiya Tanaka³, Tsutomu Takeuchi⁴, Jeffrey Curtis⁵, Ted Mikuls⁶, Clementina López Medina⁷, Peter C. Taylor⁸, Nicola Tilt⁹, Bernard Lauwerys¹⁰, Baran Ufuktepe¹¹ and Thomas Huizinga¹², ¹Medical University of Vienna, Vienna, Austria, ²Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ⁴Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁵The University of Alabama at Birmingham, Birmingham, AL, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷Reina Sofia University Hospital, Cordoba, Spain, ⁸University of Oxford, Oxford, United Kingdom, ⁹UCB Pharma, Slough, United Kingdom, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹UCB Pharma, Istanbul, Turkey, ¹²Department of Rheumatology, Leiden University, Leiden, Netherlands
Background/Purpose: In patients (pts) with rheumatoid arthritis (RA), including those treated with disease-modifying antirheumatic drugs, high rheumatoid factor (RF) levels are a poor prognostic factor,…
Abstract Number: 0416 • ACR Convergence 2023
Association Between Sleep Disorders and Rheumatoid Arthritis: A Population-based Cohort Study
Rakesh Kumar¹, Edward Lovering¹, Chanakya Kodishala², Sara Achenbach³, Diego Carvalho¹, Cynthia Crowson¹, John Davis¹ and Elena Myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester Minnesota, Rochester, MN, ³Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: Some sleep disorders (SD) are more prevalent in patients with chronic inflammatory diseases, such as Rheumatoid Arthritis (RA). However, most of the research has…
Abstract Number: 0980 • ACR Convergence 2023
Temporal Trends in Incidence Rates of Seropositive and Seronegative Rheumatoid Arthritis: A Danish Nationwide Population-based Study
Bolette Soussi¹, René Cordtz², Kirsten Duch², Salome Kristensen³, Asta Linauskas⁴, Christian Bork⁵, Erik Schmidt⁶ and Lene Dreyer³, ¹Center of Rheumatic Research Aalborg, Department of Rheumatology, and Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark, ²Center of Rheumatic Research Aalborg, Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ³Center of Rheumatic Research Aalborg, Department of Rheumatology, Aalborg University Hospital, and Department of Clinical Medicine, Aalborg University, Aalborg, Denmark, ⁴Department of Rheumatology, North Denmark Region Hospital, and Department of Clinical Medicine, Aalborg University, Hjørring, Denmark, ⁵Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark, ⁶Department of Medicine and Cardiology, Viborg Regional Hospital, and Department of Clinical Medicine, Aalborg University, Viborg, Aalborg, Denmark
Background/Purpose: With growing availability of autoantibody testing and autoantibodies gaining more weight in the 2010 ACR/EULAR classification criteria of rheumatoid arthritis (RA), an increasing incidence…
Abstract Number: 1046 • ACR Convergence 2023
The Level of RF or Anti-CCP Antibody Affect Ultrasound Synovial Findings in Patients with Rheumatoid Arthritis?
Tadashi Okano¹, Kenji Mamoto¹, Yutaro Yamada¹, Shohei Anno², Yuka Domae¹, Shingo Washida¹, Asami Yagami¹, Yuko Yoshida¹, Tatsuya Koike³ and Hiroaki Nakamura¹, ¹Osaka Metropolitan University, Osaka, Japan, ²Yodogawa Christian Hospital, Osaka, Japan, ³Search Institute for Bone and Arthritis Disease (SINBAD), Shirahama Foundation for Health and Welfare, Shirahama, Japan
Background/Purpose: Positive for auto-antibodies such as rheumatoid factor (RF) and anti-citrullinated peptide antibodies (CCP) or having high autoantibody titers is associated with the progression of…
Abstract Number: 1276 • ACR Convergence 2023
Multimorbidity Burden Predicts Lower Likelihood of Remission in Patients with Rheumatoid Arthritis
Cynthia Crowson, Chanakya Kodishala, Tina Gunderson, Atkinson Elizabeth, Vanessa Kronzer, John Davis, Courtney Arment, Delamo Bekele, Thomas Mason, Lynne Peterson, Kerry Wright and Elena Myasoedova, Mayo Clinic, Rochester, MN
Background/Purpose: Seropositivity has historically been associated with poor disease outcomes in patients with rheumatoid arthritis (RA). Seronegative RA is on the rise and is associated…
Abstract Number: 1296 • ACR Convergence 2023
Decline in Incidence of Extraarticular Manifestations of Rheumatoid Arthritis: A Population-Based Cohort Study
Bradly Kimbrough¹, Cynthia Crowson¹, John Davis¹, Eric Matteson² and Elena Myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN
Background/Purpose: Extraarticular manifestations of rheumatoid arthritis (ExRA) are associated with increased disease burden and mortality. They are also common, affecting about half of patients with…
Abstract Number: 1308 • ACR Convergence 2023
Certolizumab Pegol Shows Longer Retention Rate in Comparison with Other TNF Inhibitors in Patients with Rheumatoid Arthritis and High Rheumatoid Factor Titers at Baseline. a Multicentre and Retrospective Study
Clementina López Medina¹, Jerusalem Calvo², Maria del Carmen Abalos-Aguilera³, Francisco Cepas⁴, Chamaida Plasencia-Rodríguez⁵, Ana Martinez Feito⁶, Alejandro Balsa⁵, Regina Faré-García⁷, Antonio Juan Mas⁷, Virginia Ruiz-Esquide⁸, Luis Sainz-Comas⁹, César Díaz-Torné⁹, Javier Godoy¹⁰, Isabel Anon Onate¹¹, Natalia Mena Vazquez¹², SARA MANRIQUE¹³, Marina soledad Moreno Garcia¹⁴, Rafaela Ortega Castro¹⁵ and Alejandro Escudero-Contreras¹⁶, ¹Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain, ²Reina Sofia University Hospital, Córdoba, Spain, ³Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, ⁴Maimonides Institute for Biomedical Research (IMIBIC), Córdoba, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Immuno-Rheumatology research group , Institute for Health Research (IdiPAZ), Madrid, Spain, ⁷Son Llazter University Hospital, Palma, Spain, ⁸Hospital Clinic, Rheumatology, Barcelona, Spain, ⁹Hospital de Santa Creu i Sant Pau, Barcelona, Spain, ¹⁰Jaen University Hospital, Jaen, Spain, ¹¹Hospital Universitario de Jaen, Jaen, Spain, ¹²IBIMA, Málaga, Spain, ¹³Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ¹⁴Hospital Miguel Servet, Zaragoza, Spain, ¹⁵Hospital Reina Sofía, Cordoba, Spain, ¹⁶Rheumatology Department, Reina Sofia University Hospital, Cordoba/Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Córdoba, Spain
Background/Purpose: Rheumatoid Factor (RF) is an antibody against the Fc fragment of IgG that contributes to the Rheumatoid Arthritis (RA) development. RF can bind the…
Abstract Number: 1316 • ACR Convergence 2023
Influence of Rheumatoid Factor on Serum Drug Levels of TNF Inhibitors with Different Structures in Rheumatoid Arthritis
Ana Martinez Feito¹, Chamaida Plasencia-Rodríguez², Marta Novella-Navarro², Johanna E. Gehin³, Borja Hernandez-Breijo⁴, Claudia M.Brenis⁵, Alejandro Villalba⁶, Elisa Fernandez-Fernandez⁴, Irene Monjo⁷, Dora Pascual-Salcedo⁸, Pilar Nozal⁹ and Alejandro Balsa², ¹Immuno-Rheumatology research group , Institute for Health Research (IdiPAZ), Madrid, Spain, ²Hospital Universitario La Paz, Madrid, Spain, ³Dept. of Medical Biochemistry, Oslo University Hospital, Oslo, Norway, ⁴La Paz University Hospital, Madrid, Spain, ⁵VIB-UGent Inflammation Research Center Gent, Belgium, Gent, Belgium, ⁶Rheumatology Department, La Paz University Hospital, Madrid, Spain, ⁷University Hospital La Paz, Madrid, Spain, ⁸Immuno-Rheumatology Research Group, La Paz University Hospital, Madrid, Spain, ⁹Immunology Unit in La Paz University Hospital-Idipaz, Madrid, Spain
Background/Purpose: Elevated rheumatoid factor (RF) in patients with rheumatoid arthritis (RA) is associated with higher disease activity. A significantly lower efficacy of TNF inhibitors (TNFi)…
Abstract Number: 1754 • ACR Convergence 2023
Novel and Unique Rheumatoid Factors Cross-React with Viral Epitopes in COVID-19
Maya Amjadi¹, Maxwell Parker², Zihao Zheng¹, Alex Robbins¹, Michael Denny¹, Sara McCoy³, Irene Ong¹ and Miriam Shelef¹, ¹University of Wisconsin, Madison, WI, ²University of Wisconsin-Madison, Madison, WI, ³University of Wisconsin School of Medicine and Public Health, Middleton, WI
Background/Purpose: Rheumatoid factors (RFs), polyreactive antibodies canonically known to bind two conformational epitopes of IgG, are a hallmark of rheumatoid arthritis but also can arise…
Abstract Number: 1772 • ACR Convergence 2023
Rheumatoid Arthritis-Specific Rheumatoid Factors Develop in Some COVID-19 Patients
Adam Titi¹, Ryan Adyniec², Nat Murren¹ and Miriam Shelef¹, ¹University of Wisconsin, Madison, WI, ²University of Wisconsin-Madison, Madison, WI
Background/Purpose: Rheumatoid factors (RFs), antibodies canonically known to bind two conformational epitopes of IgG Fc, are a hallmark of rheumatoid arthritis (RA) but also can…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].